Diabetes drug may help symptoms of autism-associated condition
McGill University News May 19, 2017
Metformin shows promise to treat Fragile X syndrome, an inherited form of intellectual disability.
Metformin, the most widely used drug to treat type 2 diabetes, could potentially be used to treat symptoms of Fragile X syndrome, an inherited form of intellectual disability and a cause of some forms of autism.
A new study led by researchers at McGill University, the University of Edinburgh and Université de Montréal has found that metformin improves social, behavioural and morphological defects in Fragile X mice.
Fragile X mice  animals that display symptoms associated with the disease such as increased grooming and decreased socialization  showed normal brain connections and behavioural patterns after 10 days of injection with metformin.
Nahum Sonenberg, James McGill Professor at McGillÂs Biochemistry Department and co–senior author of the new study published in Nature Medicine, said the findings offer hope for patients with Fragile X syndrome. ÂThis is some of the most exciting research work in my career, as it offers great promise in treating a pernicious genetic disease for which there is no cure, he said.
Christos Gkogkas, ChancellorÂs Fellow at the University of EdinburghÂs Patrick Wild Centre explained that Âmetformin has been extensively used as a therapy for type 2 diabetes for more than 30 years, and its safety and tolerability are well documented.Â
ÂThis makes the drug an ideal candidate for fast–tracked clinical trials and, if all goes well, a readily available drug for the treatment of Fragile X syndrome, added Jean–Claude Lacaille, Canada Research Chair in Cellular and Molecular Neurophysiology and professor in the Department of Neurosciences at Université de Montréal and a major collaborator on the study.
In the past few years, metformin has generated extensive interest for its potential in treating numerous health problems such as cancer, cardiovascular diseases, neurological diseases and aging.
ÂBasically, itÂs something like a wonder drug, Sonenberg said.
The study suggests that metformin might also be used to treat other autism spectrum disorders, said Ilse Gantois, a research associate in SonenbergÂs lab at McGill.
ÂWe mostly looked at the autistic form of behaviour in the Fragile X mouse model, explained Gantois, who is co–lead author with McGill researchers Arkady Khoutorsky and Jelena Popic. ÂWe want to start testing other mouse models to see if the drug could also have benefits for other types of autism.Â
The study also established that metformin restores some of the molecular pathways disrupted in the absence of the FMR1. The next step will be to understand the drugÂs exact role in these pathways.
ÂIt is a simple story in terms of the description of the corrections allowed by the drug, Sonenberg said. ÂWhat is more complicated is the molecular mechanism, how exactly it works. We need to study, in the lab, what molecules metformin interacts with and what cellular functions are affected.Â
Moreover, the drug could be tweaked Âto be more efficient than metformin and repurposed, for example, for other disorders, he added.
The results were published in the journal Nature Medicine.
Go to Original
Metformin, the most widely used drug to treat type 2 diabetes, could potentially be used to treat symptoms of Fragile X syndrome, an inherited form of intellectual disability and a cause of some forms of autism.
A new study led by researchers at McGill University, the University of Edinburgh and Université de Montréal has found that metformin improves social, behavioural and morphological defects in Fragile X mice.
Fragile X mice  animals that display symptoms associated with the disease such as increased grooming and decreased socialization  showed normal brain connections and behavioural patterns after 10 days of injection with metformin.
Nahum Sonenberg, James McGill Professor at McGillÂs Biochemistry Department and co–senior author of the new study published in Nature Medicine, said the findings offer hope for patients with Fragile X syndrome. ÂThis is some of the most exciting research work in my career, as it offers great promise in treating a pernicious genetic disease for which there is no cure, he said.
Christos Gkogkas, ChancellorÂs Fellow at the University of EdinburghÂs Patrick Wild Centre explained that Âmetformin has been extensively used as a therapy for type 2 diabetes for more than 30 years, and its safety and tolerability are well documented.Â
ÂThis makes the drug an ideal candidate for fast–tracked clinical trials and, if all goes well, a readily available drug for the treatment of Fragile X syndrome, added Jean–Claude Lacaille, Canada Research Chair in Cellular and Molecular Neurophysiology and professor in the Department of Neurosciences at Université de Montréal and a major collaborator on the study.
In the past few years, metformin has generated extensive interest for its potential in treating numerous health problems such as cancer, cardiovascular diseases, neurological diseases and aging.
ÂBasically, itÂs something like a wonder drug, Sonenberg said.
The study suggests that metformin might also be used to treat other autism spectrum disorders, said Ilse Gantois, a research associate in SonenbergÂs lab at McGill.
ÂWe mostly looked at the autistic form of behaviour in the Fragile X mouse model, explained Gantois, who is co–lead author with McGill researchers Arkady Khoutorsky and Jelena Popic. ÂWe want to start testing other mouse models to see if the drug could also have benefits for other types of autism.Â
The study also established that metformin restores some of the molecular pathways disrupted in the absence of the FMR1. The next step will be to understand the drugÂs exact role in these pathways.
ÂIt is a simple story in terms of the description of the corrections allowed by the drug, Sonenberg said. ÂWhat is more complicated is the molecular mechanism, how exactly it works. We need to study, in the lab, what molecules metformin interacts with and what cellular functions are affected.Â
Moreover, the drug could be tweaked Âto be more efficient than metformin and repurposed, for example, for other disorders, he added.
The results were published in the journal Nature Medicine.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries